Core Insights - CalciMedica is conducting a Phase 2 KOURAGE trial of Auxora™ for acute kidney injury (AKI) and expects data by the end of 2025 [1][4] - A post-hoc analysis from the Phase 2 CARDEA trial indicated a 62.7% relative reduction in mortality for patients treated with Auxora compared to placebo [1][4] - The company has sufficient cash to fund operations into mid-2026, with a cash position of $18.7 million as of December 31, 2024 [10] Clinical Updates - Enrollment in the KOURAGE trial is ongoing, targeting 150 patients with severe AKI and acute hypoxemic respiratory failure [4] - The CARDEA trial analysis included 38 patients with AKI and respiratory failure, showing a 29.3% absolute reduction in mortality at day 30 [4] - An end-of-Phase 2 meeting with the FDA is planned for mid-2025 to discuss a Phase 3 program for acute pancreatitis with systemic inflammatory response syndrome (SIRS) [4] Financial Performance - Research and development expenses decreased to $14.5 million in 2024 from $15.9 million in 2023, primarily due to reduced personnel expenses [10] - General and administrative expenses significantly decreased to $9.7 million in 2024 from $22.2 million in 2023, also due to reduced personnel costs [10] - The net loss for 2024 was $13.7 million, a reduction from a net loss of $34.4 million in 2023 [10][15] Corporate Developments - The company secured a credit facility of up to $32.5 million from Avenue Capital Group, providing financial support for ongoing operations [7] - Leadership was strengthened with the appointment of Stephen Bardin as Chief Financial Officer in November 2024 [9] - Alan Glicklich, M.D., was appointed to the Board of Directors in January 2025, bringing over 20 years of biotechnology experience [9]
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates